Zenas BioPharma, Inc.
Financials
Valuation Metrics
Zenas BioPharma, Inc.'s Market Cap is $2.08B. At end of 2025 it was $1.69B. Ranked #1996 of 3,121 in US market (top 64%), #758 of 1,463 on NASDAQ (top 52%), #136 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 51%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.08B | US#1,996/3,121 Sec#136/266 |
| Revenue | $1M | US#2,876/3,121 Sec#191/266 |
| Net Income | $-484M | US—/3,121 Sec—/266 |
| Total Assets | $702M | US#2,628/3,121 Sec#132/266 |
| Net Assets | $247M | US#2,604/3,121 Sec#172/266 |
| Employees | 167 | US#2,526/3,121 Sec#137/266 |
| Value | ||
| P/B | 8.43x | US#2,555/3,121 Sec#185/266 |
| P/S | 208.37x | US#2,962/3,121 Sec#188/266 |
| FCF Yield | -10.84% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -196.03% | US#2,843/3,121 Sec#218/266 |
| ROA | -69.03% | US#3,033/3,121 Sec#239/266 |
| Op. Margin | -47557.30% | US#2,885/3,121 Sec#193/266 |
| Revenue Growth | -93.33% | US#2,769/3,121 Sec#182/266 |
| Financial Health | ||
| Debt Ratio | 183.97% | US#1,711/3,121 Sec#196/266 |
| Total Debt | $390M | US#2,012/3,121 Sec#73/266 |
| FCF | $-226M | US#2,800/3,121 Sec#217/266 |
| Cash | $197M | US#1,748/3,121 Sec#111/266 |
| Current Ratio | 9.93x | US#260/3,121 Sec#82/266 |
| Performance | ||
| 1Y Return | 67.65% | US#375/3,121 Sec#84/266 |
| 1M Return | 0.19% | US#919/3,121 Sec#90/266 |
| From 52W High | -28.32% | US#1,974/3,121 Sec#156/266 |
| 1Y MDD | -64.79% | US#2,879/3,121 Sec#228/266 |
| Trading | ||
| Volume | 513,544 shares | US#2,000/3,121 Sec#210/266 |
| Trading Value | $17M | US#2,020/3,121 Sec#157/266 |
| Per Share | ||
| EPS | $-7.43 | US—/3,121 Sec—/266 |
| BPS | $3.79 | US#2,390/3,121 Sec#145/266 |
Company Info
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.